Skip to content

To evaluate the efficacy of antidandruff hair leave on product on healthy human subjects

Evaluating Anti dandruff Efficacy of Hair Leave on Products on Healthy Human Subjects Based on Half Head Application Design. - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/05/013774
Enrollment
50
Registered
2018-05-08
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Antidandruff serum 1.Test product ADLOM198 2.Test product ADLOS226 : Dose: 3.0 gm for each application. Duration: 10 Weeks for each subject. Frequency: Weekly Twice. Control Interventi

Sponsors

ITC Life Science and Technology Centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Subjects who are willing to give signed informed consent and who consent to abide by the study protocol and restrictions for the entire study duration. 2.A mixed population of healthy male and female subjects in the age group of 20-45 yrs. 3.Subjects with preferably lengthy hair (for female subjects) but not mandatory. 4.Subjects with moderate to severe scalp dandruff score (with dandruff on both sides of the scalp). 5.Subjects with moderate to severe scalp itch score (Scoring based on subjectâ??s feedback) 6.Subjects who have not participated in a similar investigation in the past four weeks. 7.Subjects who are not sensitive to the ingredients of the test product (As disclosed by the subjects or as observed during the Skin sensitivity test).

Exclusion criteria

Exclusion criteria: 1.Subjects with a known history or present condition of allergic response to any shampoo or conditioner. 2.Subjects having communicable skin/scalp infections or other skin disease (e.g. psoriasis, atomic dermatitis or other cutaneous manifestations), which could interfere with the test results as diagnosed by Dermatologist. 3.Subjects with severe hair fall due to endocrine disorders as diagnosed by dermatologist or revealed through oral interview. 4.Subjects on medications (steroids, antihistamines, antimicrobials), which would compromise the study results (Subjects inputs). 5.Female subjects who are pregnant (determined by Urine pregnancy test), lactating, or planning pregnancy during the course of the study (Subjects inputs). 6.Subjects with signs and symptoms of systemic and / or chronic illness (As diagnosed by Dermatologist) 7.Subjects who are regular users of anti- dandruff shampoo/ undergoing therapy for dandruff (Subjects inputs).

Design outcomes

Primary

MeasureTime frame
-Significant difference between the test products in conferring a reduction in dandruff symptoms. -Significant difference between the test products in delaying the recurrence of dandruff symptoms. -Significant difference between the test products in conferring improvement in hair quality and scalp health. Timepoint: Approximately 10 Weeks for each subjects

Secondary

MeasureTime frame
-No significant difference between the test products in tolerability and efficacy in conferring scalp and hair attribute benefits.Timepoint: Approximately 10 Weeks for each subjct.

Countries

India

Contacts

Public ContactDrMukesh Ramnane

M.S Clinical Research Pvt Ltd

mukesh.ramnane@mscr.in080-40917253

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026